ABSTRACT
BACKGROUND: Kinesiotaping (KT) is widely used in several musculoskeletal disorders particularly in shoulder pain. However, literature shows controversial results regarding the effect of KT on shoulder pathology. The aim of this study was to assess the clinical effects of KT in the short term on rotator cuff tendinopathy (RCT). METHODS: A randomized controlled double-blind clinical trial was conducted. The sample consisted of 50 subjects (25 per group). Patients were randomly assigned to the KT group (to receive therapeutic KT application) or to the placebo group (to receive sham KT application). Taping was applied every 4 days, a total of three times during the study period. We assessed the patients at baseline, at the end of taping period (D12), and at one-month post-taping (D30). Primary outcome was assessed through the Arabic version of the Disabilities of the Arm, Shoulder and Hand questionnaire (DASH). Secondary outcomes were assessed through Visual Analogue Scale (VAS) for pain intensity at rest (VASr), during active movement (VASm), and at night (VASn). RESULTS: There were no significant differences between the two groups in the demographic and clinical characteristics and the pre-test scores. Results of repeated measures ANOVA showed significant improvement in DASH scores and in VAS for pain (at rest, during active movement and at night) from D12 in both groups. The use of ANCOVA, controlling for pre-test scores, showed no significant differences between groups, except for VASm at D30. CONCLUSION: This study showed that the standardized therapeutic KT used for shoulder pain was not superior to a sham KT application in improving pain and disabilities in patients with RCT. TRIAL REGISTRATION: The study was retrospectively registered on Pan African Clinical Trial Registry (identification number: PACTR202007672254335) on 21/07/2020. https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12200.
Subject(s)
Athletic Tape , Rotator Cuff Injuries , Tendinopathy , Humans , Rotator Cuff , Shoulder Pain/diagnosis , Shoulder Pain/therapy , Tendinopathy/diagnosis , Tendinopathy/therapy , Treatment OutcomeABSTRACT
To assess the modalities and current practices in gout management reported by Moroccan rheumatologists. We performed a cross-sectional online survey using a questionnaire e-mailed to 360 rheumatologists included 30 multiple-choice questions. 105 rheumatologists responded to the survey with 29% of response rate. The number of gout patients seen per month was five (3-9); they were referred in 58.7% by a general practitioner. The clinical presentation of gout patients was dominated by gout crisis in 71%, and the association gout crisis and gouty arthropathy accounted for 19% of severe forms. 40% of rheumatologists apply the 2015ACR/EULAR classification criteria. Obesity accounted for 85.7% of the associated comorbidities. The most commonly prescribed Urate-lowering therapy (ULT) was allopurinol in 81.3% (± 12). 48% of rheumatologists reported starting allopurinol at 200 mg daily and associated it with colchicine during the first 6 months by 33.3%. The determination of uric acid levels was monitoring in 76.2% every 3 months. Administration of ULT to asymptomatic hyperuricemia was found in 69.5% when patients had renal complications, while only 14.3% recommended dietary and lifestyle measures. The median duration for therapeutic education was 15 min (10, 20). In 96.2%, the education of the patient was done orally. 93.3% of rheumatologists inform their patients on how to manage a gout attack, and 96.2% on the measures of hygiene and diet has adopted. Our survey gives an insight into the elements that should be improved in the management of gout by the Moroccan rheumatologists. It highlights the need to standardize the management of gout, hence the importance of developing Moroccan recommendations on gout.